Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
WOW 75% UP SO FAR !!! GOGO MRES.
Did he mention that his technology would never work or exist by any means... Or that his technology is a complete lie and a big dream that cannot work base on all our physic knowledge????
And did he mention that WDRP his being run by BIG CRIMINAL AND FRAUDSTERS that are actually ( i mean at this second ) investigated by the SEC and the AMF...
PURE SMOKE IN THE EYES
did he ??
pfff
LOLOl
WHAT RUN??? YOU MEAN THE RUN DOWN!!!
here s a little,
1- it s being run by a couple of MTL Fraudsters
2- already been promoted by PSC, who have been taken down by the SEC and the AMF recently..
3- their technologies just CANNOT exist by all of our physic laws...
4- they are at this moment being investigate by the AMF the SEC and other authorities, in part of a big investigation in MTL...
now just wait for the raid and loose everything...
MRES IS UP 150% SINCE 9 MONTH AGO !!!
PUURE GOOOOLD !!!!
Yes. the new management took control of MRES in June, Cortellazzi s share have been given back to the treasury to make sure he s not around anymore. MRES change his vocation and went in the Biotechnology sector along whit this, a change of all the directors and principals have been made... From Mining Guy Barry Somerveil the president of the company have been change to General Specialist Doctor Dr Poulin.
Now She is just following her path to SUCCESS !!!
BOOM 50% UP TODAY.. GO MRES!!!
VOLUME IS BUILDING STRONGER AND STRONGER !!!
NEWZ OUT
A brief explanation of Dopamine-Beta-hydroxylase (DBH) - SymPath(R) : In Vitro Diagnostic Test to distinguish anxious disorders
Neuro-Biotech Corp. Common Stock (USOTC:MRES)
Intraday Stock Chart
Today : Thursday 30 September 2010
Click Here for more Neuro-Biotech Corp. Common Stock Charts.
Neuro-Biotech Corporation (PINKSHEET: MRES)(OTCQB:MRES) in acquiring licenses to commercialize 12 Neuro-biomarkers has first focused on SymPath(R) and is now ready to give you the opportunity to shed some light about this Neuro-biomarker of the Sympathetic Nervous System (SNS). Here is a peak into the research behind the Neuro-blood testing that will be available to all patients through their health system.
It is important to pinpoint that DBH was first described in 1955 and reviewed in 1965 by Kaufman & Friedman. In 1974, Geffen has described DBH as a biomarker of the SNS. At that moment, in the Journal of Neurochemistry, Roberge et al. (1976) have published that an inversed relationship occurs between the brain dopamine and serotonin content on a neuroanatomical basis. As in the brain, the noradrenergic and serotoninergic pathways are closed together at the level of the locus coereleus, the raphei nuclei and the brainstem, respectively (Roberge & Poirier, 1973, 1974) and that, to an increased dopamine content following the administration of L-DOPA in monkeys did not correspond to increased noradrenaline content within several neuroanatomical structures in the brain. Moreover, it was demonstrated that DBH was involved in anxiety and depression (Friedman et al., 1984).
In this respect, working with 15 to 18 different brain structures, the effects observed in the structures related to the motor system were different to those noted within the mesolimbic system - it was the starting point to understand how DBH is working to be the key enzyme in the noradrenaline synthesis.
The kinetic DBH enzyme activity and biochemical parameters were respectively studied in the brain, adrenals and blood of different species such as monkeys, cats, rats, rabbits, fish, mink, sheep and human beings using various stressful situations and several drugs. In this respect, Parkinson Disease, Alzheimer, Schizophrenia and stress related diseases were respectively studied working with catecholaminergic, serotoninergic and cholinergic pathways related to the motor system (monkeys), to the memory mechanisms (cats), learning disabilities (human beings), anorexia nervosa (human beings), bulimia (developing a model with rats in regards to people waiting for bypass surgery). As the relationship between the brain and the HPAS Axis is a key issue in stress related diseases, various stressful situations such as, cold exposure, immobilization and treadmill in rats, hypoxia in fish, a workload in a swimming pool in humans, food behaviours using cats, rabbits, rats, minks and fishes. Finally, in rats, the effects of spontaneously hypertensive state on DBH enzyme activity were compared to clinical data obtained from a group of post MI people.
DBH, the synthesising enzyme of noradrenaline from dopamine, is a copper and ascorbate dependent. Noradrenaline, a vasoconstrictor, is released within the blood from the SNS with DBH. Its biochemical and kinetic parameters were studied in brain, adrenals and serum (Fortin & Roberge, 1992) and in human beings to figure out how a commercial kit could be useful for different clinical purposes on a daily basis (US Patent (#5879902) and Canadian Patent (# 2204179)). In human beings, several studies were conducted involving different sexes, age, Rhesus factor, blood groups, seasonal variations, diurnal rhythms and endocrine functions..
In summary, noradrenaline, a vasoconstrictor, is released within the blood from the SNS with DBH. A commercial kit named SymPath(R) has been developed to quantitatively standardize the measurement kit of the specific activity of DBH released within the blood from the SNS. In this regards, the clinical data allow to distinguish anxious disorders from depressive disorders - that is a breakthrough in neurosciences.
Contact:
Neuro-Biotech Corp.
Dr Claude Poulin
41 61 500 05 16
info@neuro-agora.com
www.neuro-biotechcorp.com
SOURCE Neuro-Biotech Corp.
hmmm...that s sound a lot like WDRP lol
If only you knew kid, if only you knew !!!
here s a little,
1- it s being run by a couple of MTL Fraudsters
2- already been promoted by PSC, who have been taken down by the SEC and the AMF recently..
3- their technologies just CANNOT exist by all of our physic laws...
4- they are at this moment being investigate by the AMF the SEC and other authorities, in part of a big investigation in MTL...
now just wait for the raid and loose everything...
pfff
years 2000 , pfff , USELESS
like i said 11 OTHER NOT ONLY THE SYMPATH!!!
You got it Tracker, this one is a Gold Nugget !!
THERE IS 11 OTHERS, NOT ONLY THE SYMPATH....
Might means that something is coming, after all that time off...
NEWS OUT, LIST OF PRODUCT, PUURE GOLD!!!
NEURO-BIOTECH DISCLOSES ITS LIST OF LICENSES
Neuro-Biotech Corp. Common Stock (USOTC:MRES)
Intraday Stock Chart
Today : Tuesday 28 September 2010
Click Here for more Neuro-Biotech Corp. Common Stock Charts.
Neuro-Biotech Corporation (PINKSHEETS: MRES) (OTCQB: MRES) discloses its list of licenses.
NEURO # 1
SymPath(R)
TO EVALUATE THE SYMPATHETIC NERVOUS SYSTEM THROUGH THE ENZYME, DOPAMINE Beta- HYDROXYLASE (DBH), THAT IS RELEASED WITH NORADRENALINE WITHIN THE BLOOD AND DISTINGUISH BETWEEN DEPRESSIVE STATES AND ANXIOUS DISORDERS.
NEURO # 2
AXIS(TM)
TO QUANTITATIVELY AND DIRECTLY EVALUATE THE HYPOTHALAMO-PITUITARY ADRENAL AXIS THROUGH ENDING MOLECULES FORMED FROM THE RELEASED ACTH WITHIN THE BLOOD AND ACTING ON DESMOLASE ENZYME ACTIVITY, REQUIRING CHOLESTEROL BIOAVAILABILITY.
NEURO # 3
TETRIC(TM)
TO UNDERSTAND THE RELATIONSHIP BETWEEN CONSTITUTIVE & INDUCTIVE DBH ENZYME IN ORDER TO DISCRIMINATE PSYCHOAFFECTIVE AND MENTAL DISTURBANCES, THROUGH SIEVING MOLECULAR WEIGHT.
NEURO #4 and #5
ARE ONE PLATFORM FOR ALL OF THEM: 5-HT / 5HIAA DA / DOPAC / HVA NA / VMA / A MELATONIN TO UNDERSTAND THE RELATIONSHIP BETWEEN NEUROTRANSMITTERS, THE TURNOVER OF THEIR METABOLITES, AND TO FIGURE OUT THE CLINICAL PREDOMINENCE
NEURO # 6
TRYPTYR
TO EVALUATE THE BIOAVAILIBILITY OF TWO MAIN NEURO-TRANSMITTERS SUBSTRATES AND THEIR IMPACT IN BRAIN 5-HT AND NA SYNTHESIS.
NEURO #7
DIVAN
TO EVALUATE THE BIOAVAILABILITY OF THE EIGHT (8) ELECTROLYTES AND THEIR RELATIONSHIPS INVOLVED IN THE CNS.
NEURO # 8
GACHA
TO EVALUATE THE GABA AND ACETHYLCHOLINE RELATIONSHIP AT THE CELLULAR ENERGETIC CAPACITY.
NEURO # 9
FREERAD
TO MEASURE THE FREE RADICALS AND DETERMINE THEIR PREDOMINANCE IN REGARDS TO THE AXIS ACTIVITY.
NEURO # 10
MAOS
TO DETERMINE THE MAO TYPE A OR B ACTIVITY AND TO DEFINE THE CLINICAL PATIENT PROFILE IN RESPECT TO EXPECTED DIAGNOSIS AND THERAPEUTIC APPROACHES.
NEURO # 11
NEURENDOM
TO DEFINE THE MALE NEUROENDOCRINE PROFILE IN ORDER TO DIAGNOSE NEURO-PSYCHO-AFFECTIVE ENDOCRINE ILLNESS.
NEURO # 12
NEURENDOF
TO DEFINE THE FEMALE NEUROENDOCRINE PROFILE IN ORDER TO DIAGNOSE NEURO-PSYCHO-AFFECTIVE ENDOCRINE ILLNESS.
SOURCE Neuro-Biotech Corp.
http://starglobaltribune.com/category/health
, look a bit down
again, WHO CARES ??? 3 years ago NOT RELEVANT!!!
The Neuro-Biotech Corporation is a global biotechnology enterprise, which is renowned for its expertise in clinical neuroscience diagnostic testing. The clinical neuroscience diagnostic testing services offered by Neuro-Biotech are both reliable and non-invasive, and complement more conventional clinical laboratory testing procedures, in providing general practitioners as well as specialists with diagnostic tools to be used in the diagnosis and analysis of stress-related diseases and mental-health disorders, such as Alzheimer’s disease and Schizophrenia.
Neuro-Biotech’s expertise on the human brain, its communication system with the rest of the body, as well as its impact and influence on the peripheral systems of the body, can be attributed to over twenty years of continuous research and development work by the company, and forms the basis for the in vitro diagnostic blood testing services it offers. The company hopes that the diagnostic and testing services it offers will help to detect, monitor and even prevent the occurrence of a wide variety of conditions and diseases such as Chronic Fatigue Syndrome (CFS), Alzheimer disease, Depression and Schizophrenia.
'THE STAR GLOBAL TRIBUNE' IS TALKING ABOUT NEURO.
http://starglobaltribune.com/2010/alzheimers-disease-treatment-tests-for-early-detection-2070
BUILDING VOLUME & PPS GOING UP , NIIIICE DAY!!!
Nice, Good Find! Thanks for posting it !
She is becoming BETTER and BETTER ...All this sounds realy good, something is coming for sure !!!
They are getting ready to sell!!!
WOW, VOLUME IS BUILDING MORE AND MORE!!!
UP 18% ON GOOD NEWS, VOLUME ID BUILDING!!!
OTHER GREAT NEWS OUT!!!
Neuro-Biotech's Solution for a Doctor near You: Early Detection for Alzheimer's and Chronic Fatigue Syndrome!
Neuro-Biotech Corp. Common Stock (USOTC:MRES)
Intraday Stock Chart
Today : Monday 20 September 2010
Click Here for more Neuro-Biotech Corp. Common Stock Charts.
Neuro-Biotech Corporation (PINKSHEETS: MRES) (OTCQB: MRES) is a worldwide based biotechnological enterprise involved in the unique international niche of clinical neuroscience diagnostic testing. Neuro-Biotech's presently has the opportunity to market 12 clinical "Neuro Blood Tests" through partnerships. Neuro-Biotech's proprietary diagnostic tests are without equal in being rapidly done as an essential complement to current clinical laboratory testing procedures, by being non-invasive, sensitive, and reliable. This will provide general practitioners and specialists alike, useful medical parameters in the analysis and treatment of workplace stress-related diseases and mental-health disorders, such as Alzheimer's.
As a result of more than 20 years of research and development (R&D), Neuro-Biotech Corp.'s specific expertise is the understanding of the communication between the brain and the human body and their various influences on the peripheral systems, in order to maintain the internal equilibrium of a person's state of mind.
This exclusive understanding of the relationships between the neurotransmitter families within the brain led to the development of a portfolio of in vitro diagnostic blood tests. They will be used for the detection, prevention, monitoring and follow-up of the major psycho-social environmental diseases. They can be stress-related, socio-professional and occupational diseases, such as Chronic Fatigue Syndrome (CFS), Great Anxiety (GA), Panic Syndrome (PS); Cardiovascular diseases like Essential Hypertension or Arrhythmia; Neurodegenerative diseases such as Alzheimer or Parkinson's Disease as well as Mental-Health Disorders in the vein of Depression and Schizophrenia
Caregivers can now evaluate and establish an individual's ability to react to stress by monitoring bio-indicators within the blood or other biological fluids. Efficient and improved patient supervision, treatment and follow-up care can be instituted.
Clinical Neuroscience-related diseases can be difficult
to diagnose and complex to treat.
If we don't know the full state of health of an individual
and the progression of the therapy...
How can we truly manage the care and rehabilitation?
Neuro-Biotech Corp. has the solution!
SOURCE Neuro-Biotech Corp.
HERE S THE BEST PART
Neuro-Biotech Corp's goals have resulted in a new and reliable portfolio of quantitative blood tests that provide general practitioners and specialists useful clinical parameters for the diagnosis of neuroscience-related diseases or physio-pathological impairments. This is accomplished by identifying abnormal readings of specific bio-markers within the blood or other biological fluids. Neuro-Biotech Corp's diagnostic tests are without equal in being non-invasive, sensitive, reliable and rapidly done as an essential complement to current clinical laboratory
testing procedures.
Neuro-Biotech presently has the opportunity to commercialize 12 clinical Neuro Blood Tests through partnerships, as specialized blood testing for a progressive clinical neuroscience investigation of targeted diseases, thus selectively monitoring specific neuro-biomarkers related to the neuro-immune and endocrine systems. Caregivers will now be able to evaluate and establish an individual's ability to react to stress and, to identify the appropriate neuro-endocrine and immune dysfunctioning. By monitoring bio-indicators related to workplace stress-related diseases and mental-health disorders, efficient patient treatment and follow-up are feasible.
yes there is,
it s not cuz you don t have them that they don t exist!!!
LOLOL
and don t ask for links, i wont post them here!!!
Clinical testing have been done, R&D already completed!!!
VERY GOOD NEWZZ OUT!!!
Early Detection for Alzheimer's, Chronic Fatigue Syndrome and Other Diseases: In Vitro Diagnostic Tests from Neuro-Biotech Corp.
Neuro-Biotech Corp. Common Stock (USOTC:MRES)
Intraday Stock Chart
Today : Monday 20 September 2010
Click Here for more Neuro-Biotech Corp. Common Stock Charts.
Neuro-Biotech Corporation (PINKSHEETS: MRES)(OTCQB: MRES) is a worldwide biotechnological enterprise involved in the unique international niche of clinical neuroscience diagnostic testing. Neuro-Biotech Corp. uses proprietary molecular nanotechnology IVDDs (in vitro diagnostic devices) for the quantitative measurement of blood parameters to evaluate the input and output of the brain through specific neuro-biomarkers. As a result of more than 20 years of R&D, Neuro-Biotech Corp.'s specific expertise in clinical neurosciences applied enzymology is dedicated to the understanding of the relationship between the neurotransmitter families within the brain and their various influences on the peripheral systems involving the Hypothalamo-Pituitary Adreno-Sympathetic (HPAS) Axis. The HPAS Axis manages body mechanisms against stressful situations in order to maintain the homeostasis responsible for the resistance of the organism to its psycho-socio-environment through psycho-neuro-immune and endocrine systems.
This unique understanding of the communication between the brain and the human body, has led to the development of in vitro diagnostic blood tests. They are used for the detection, prevention, monitoring and follow-up of the major stress-related, socio-professional and occupational diseases, such as Chronic Fatigue Syndrome (CFS), Great Anxiety (GA), Panic Syndrome (PS), Neuropathies or Fibromyalgia (FM), Cardiovascular diseases like Essential Hypertension or Arrhythmia, Neurodegenerative diseases such as Alzheimer and Parkinson Diseases as well as Mental-Health Disorders in the vein of Depression and Schizophrenia.
Neuro-Biotech Corp's goals have resulted in a new and reliable portfolio of quantitative blood tests that provide general practitioners and specialists useful clinical parameters for the diagnosis of neuroscience-related diseases or physio-pathological impairments. This is accomplished by identifying abnormal readings of specific bio-markers within the blood or other biological fluids. Neuro-Biotech Corp's diagnostic tests are without equal in being non-invasive, sensitive, reliable and rapidly done as an essential complement to current clinical laboratory
testing procedures.
Neuro-Biotech presently has the opportunity to commercialize 12 clinical Neuro Blood Tests through partnerships, as specialized blood testing for a progressive clinical neuroscience investigation of targeted diseases, thus selectively monitoring specific neuro-biomarkers related to the neuro-immune and endocrine systems. Caregivers will now be able to evaluate and establish an individual's ability to react to stress and, to identify the appropriate neuro-endocrine and immune dysfunctioning. By monitoring bio-indicators related to workplace stress-related diseases and mental-health disorders, efficient patient treatment and follow-up are feasible.
Clinical Neuroscience-related diseases can be difficult to diagnose
and complex to treat.
If we don't know at what point an individual gets sick...and... at
what point he's better...
How can we manage the care and rehabilitation ?
Neuro-Biotech Corp. has the answer... that is...
EARLY DETECTION, MONITORING & APPROPRIATE FOLLOW-UP
yea back in 2007-2008 NOT RELEVANT ... have something recent in your pocket ??? something that can be use NOW???
FIRST that doesn t proove anthing at all, SECOND the raid by the AMF have nothing to do whit HRRN Nor the raid by the Revenue Quebec, THIRD the two raid WERE NOT CONNECTED, nothing to do with each other...
on that good night all !!!
by the way Cortellazzi sold ALL of his shares LONG TIME AGO when he got into some trouble ( needed $$$ )
any proof ???LOLOL...
yea whit a 25 cents transaction WHO CARES!!! that s a MARKET MAKER playing!!!
doesn't apply here, the only medical device needed is a NEEDLE !!! to put the blood in SOMETHING ( the test ) no medical device, only the need need to be approve...
NO need for Health Department approval for IN VITRO TESTING... only the needle need to be approve !!! Because it s the only thing to touch the body !!!
NEWS OUT !!!
Mr Claude Poulin nominated as President and CEO of Neuro-Biotech Corp.
Date : 09/17/2010 @ 4:35PM
Source : PR Newswire
Stock : Neuro-Biotech Corp. Common Stock (MRES)
Quote : 0.025 0.0 (0.00%) @ 3:45PM
Mr Claude Poulin nominated as President and CEO of Neuro-Biotech Corp.
Neuro-Biotech Corp. Common Stock (USOTC:MRES)
Intraday Stock Chart
Today : Saturday 18 September 2010
Click Here for more Neuro-Biotech Corp. Common Stock Charts.
Neuro-Biotech Corp. (PINKSHEETS: MRES) (OTCQB: MRES) announces the nomination of Doctor Claude Poulin as President and CEO.
Mr Barry Somervail comments on today's announcement "Following the change of the Company's direction during the summer of 2010, I stayed on as a member of board of directors in order to facilitate the transition process, and now that this process is complete I am pleased to announce the relinquishment of my position and duties to Dr. Poulin.
Dr. Claude Poulin, 71, a general practitioner with over 40 years of experience, owns and operates a Lachute medical clinic where he continues to practice to this day. Dr. Poulin will bring his medical experience and expertise, as well as his knowledge of patients to the board. He is also looking forward to highlighting the value of the various applications of Neuro-Biotech products within the medical community.
The appointment of Dr. Claude Poulin became effective upon the filing of the 8k Form with the relevant authorities.
Forward Looking Statements
This release contains statements that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Act of 1995. Certain statements in this press release may contain words such as "anticipates," "believes," "could," "expects," "intends," "may," "projects," "targets" and other similar language that is considered forward-looking statements. These forward-looking statements are subject to certain risks and uncertainties and persons reading this release are cautioned that such statements are only predictions, and that the Company's actual future results or performance may be materially different. The Company disclaims any intention or obligation to update or revise forward-looking information, whether as a result of new information, future events, or otherwise, could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
SOURCE Neuro-Biotech Corp
UP 14% END OF THE DAY !!!
so what that not what i am talking about... that have nothing to do with MRES...